Finland - More stringent blood donor testing requirements
2015 Mapping exercise

Colour key	
	Minimum requirements as set out in the 2004/33/EC Directive
	More stringent testing - legally binding on national level
	More stringent testing - recommended on national level
	Not legally binding and not recommended on national level

Test	Test/ technique	Legally binding	Recommendation on national level	Recommending authority/ service/ association	Type of blood donation (blood for transfection or plasma for fractionantion)	Circumstances for application/ donor profile	Regional differences	Further comments
Basic testing								
Blood group testing	AB0 typing	YES	YES	EDQM/CoE Guide on Blood Components	whole blood/ blood components for transfusion	all donations	NO	ABO/RhD-typing is performed on every donation, although not legally required for plasma for fractionation.
	RhD typing	YES	YES	EDQM/CoE Guide on Blood Components	whole blood/ blood components for transfusion	all donations	NO	ABO/RhD-typing is performed on every donation, although not legally required for plasma for fractionation. Additional testing for weak RhD according to (inter)national blood grouping praxis.
	Other, please specify: Kell, RHCE, screening for irregular erythrocyte antibodies, more extensive phenotyping	NO	YES	EDQM/CoE Guide on Blood Components	both	No testing requirement but the blood establishment performs additional testing. Kell and RHCE: all donors. Screening for **irregular antibodies**: first-time donors and after pregnancy or bloodtransfusion since the last donation. More extensive phenotyping: selected donors.	NO	Serological and molecular techniques.
HLA testing	HLA/ Technique not specified						NO	Based on general international praxis/standards for blood services.
	HLA Ab	NO	YES	European Federation for Immunogenetics, Standards: http://www.efiweb.eu/efi-committees/standards-committee.html	both	HLA Ab testing of donors is performed in case of a suspected TRALI-transfusion reaction.		
	HLA Ag							
	HLA gene	NO	YES	as above	blood components for transfusion	Selected donors are tested for donation of HLA-typed platelets		
	Other technique							
Disease testing								
VIRAL								
HIV 1 and HIV 2	**Anti-HIV 1**	YES	NO	N/A	both	all donations	NO	
	Anti-HIV 2	YES	NO	N/A	both	all donations		
	HIV 1p24	YES	NO	N/A	both	all donations		
	HIV NAT pool or ID	YES	NO	N/A	both	HIV NAT ID in use.		
	HIV NAT ID							
	Other technique							
Hepatitis B	**HBs Ag**	YES	NO	N/A	both	all donations	NO	Anti-HBc and anti-HBs testing is performed as additional testing for reactive HBsAg/HBV NAT-results
	Anti-HBc							
	Anti - HBs							
	HBV NAT pool or ID	YES	NO	N/A	both	HBV NAT ID in use.		
	HBV NAT ID							
	Other technique							
Hepatitis C	**Anti-HCV**	YES	NO	N/A	both	all donations	NO	
	HCV NAT pool or ID	YES	NO	N/A	both	HCV NAT ID in use.		
	HCV NAT ID							
	Other technique							
Hepatitis E								Testing of blood donors for HEV not in use. So far recommendations concern the plasma industry (Ph. Eur. requirement for HEV RNA testing of plasma pools for SD plasma).

Finland - More stringent blood donor testing requirements
2015 Mapping exercise

Test	Test/ technique	Legally binding	Recommendation on national level	Recommending authority/ service/ association	Type of blood donation (blood for transfection or plasma for fractionantion)	Circumstances for application/ donor profile	Regional differences	Further comments
Hepatitis A								HAV NAT pool testing (all donations) based on European guidelines for testing of plasma intended for plasma derived medicinal products and on contracts with the plasma fractionation industry.
HTLV-1								No HTLV-testing of blood donors (blood products universally lecodepleted)
HTLV-2								No HTLV-testing of blood donors (blood products universally lecodepleted)
Ebola Virus	Ebola/ technique not specified	NO	YES	WHO guidelines for testing of "convalescent" plasma from a patient recovered to a new ebola patient.	blood components for transfusion	donation from a person who has recovered from Ebola donating plasma for Ebola patient (convalescent plasma)	NO	No ebola patient so far in Finland.
	Ebola NAT pool or ID							
	Ebola NAT ID	NO	YES	WHO guidelines for testing of "convalescent" plasma from a patient recovered to a new ebola patient.	blood components for transfusion	donation from a person who has recovered from Ebola donating plasma for Ebola patient (convalescent plasma)		
	Other technique							
Chikungunya virus								
Cytomegalovirus								No CMV-testing of blood donors (blood products universally leucodepleted, leucodepletion is alternative for testing)
West Nile Virus*								WNV-testing not in use, travellers to a WNV-region are temporarily deferred, deferral is alternative for testing.
Dengue Virus								
Epstein-Barr virus								
Human Parvovirus B19	HPVB19/ technique not specified						NO	HPVB19 NAT pool testing is done for all donations based on European guidelines for testing of plasma intended for plasma derived medicinal products and on contracts with the plasma industry. Negative HPB19-result required also for components for intrauterine transfusion.
	HPVB19 NAT pool or ID	NO	YES	Ph Eur, Monograph 1646 (Human plasma (pooled and treated for virus inactivation))	both	all donations		
	HPVB19 NAT ID							
	Other technique							
Herpes simplex virus								
Malaria	Technique not specified						NO	For individuals with history of malaria to be accepted as donor, negative test result is required after 3 years following cessation of treatment and absence of symptoms. For individuals who have lived in a malarial area within the first 5 years of life, or for individuals with a history of undiagnosed febrile illness during or within 6 months of a visit to an endemic area, or for asymptomatic visitors to endemic areas, temporary
	Microscopy							
	Plasmodium sp . Ab	NO	YES	EDQM/CoE Guide on Blood Products	whole blood/ blood components for transfusion	According to Directive 2004/33/EC (see comments)		

Finland - More stringent blood donor testing requirements
2015 Mapping exercise

Test	Test/ technique	Legally binding	Recommendation on national level	Recommending authority/ service/ association	Type of blood donation (blood for transfection or plasma for fractionantion)	Circumstances for application/ donor profile	Regional differences	Further comments
	Plasmodium sp . Ag							endemic areas, temporary deferral can be reduced if tested negative.
	Plasmodium sp. Ag - rapid test							
	Plasmodium sp. NAT pool or ID							
	Plasmodium sp. NAT ID							
	Other technique							
Trypanosomiasis								No testing. Persons with a history of Chagas disease are permanently deferred.
Babesiosis								
Leishmaniasis								
Toxoplasmosis								
Other pathogen,								
BACTERIAL								
Treponema pallidum (Syphilis)	Technique not specified						NO	
	Microscopy							
	Anti-*T. pallidum*	NO	YES	EDQM/CoE Guid on Blood Products. Recommendations by/contracts with plasma industry.	both	Screening of all donations.		
	T. pallidum NAT pool or ID							
	T. pallidum NAT ID							
	Culture							
	Other technique							
Neisseria gonorrhoeae								
Brucellosis								
Tuberculosis								
Q-fever								
Other pathogen,								
FUNGI								
specify pathogen								

* For West Nile Virus NAT ID, see 2004/33/EC as amended by 2014/110/EU with a deadline for transposition into national law of December 31, 2015